LONDON (Reuters) – Haleon, the former consumer health arm of GSK, on Thursday reported a 16.1% increase in third-quarter reported revenue as it raised prices, and said it now expects organic sales growth of 8.0-8.5%.
The company said adjusted operating profit rose 14.9% to 725 million pounds ($825.63 million).
($1 = 0.8781 pounds)
(Reporting by Richa Naidu; Editing by Jan Harvey)
